SITC 2017 Abstract Titles – Biomarkers and Immune Monitoring

To search for abstract content based on keywords, select CTRL+F on your keyboard (or Command+F if you're using a Mac) and type a keyword to search for abstracts related to that keyword.

#

Title

Authors

Affiliations

Keywords

P1

Characterization of the tumor microenvironment and immune profile in non-small cell lung cancer

Hanny Musa1, Johannes Zimmermann2, Felix Segerer2, Moritz Widmaier2, Mindaugas Andrulis3, Andreas Ackermann1

1Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany 2Definiens AG, 80636 Munich, Germany 3Klinikum Ludwigshafen, 67063 Ludwigshafen am Rhein, Germany

Biomarkers | Immune contexture | Gene expression | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Tumor stroma | Immune suppression | Immune monitoring | Inflammation | Checkpoint blockade

P2

ADXS-PSA immunotherapy increases the magnitude and quality of prostate cancer antigen-specific T cell responses in patients with metastatic castration-resistant prostate cancer

Sandra M. Hayes1 Robert G. Petit1, Lawrence Fong2, Mark Stein3, Ronald Tutrone4, Anthony Mega5, Naomi Haas6

1Advaxis Immunotherapies, Inc, Princeton, NJ, USA 2UCSF University of California, San Francisco, CA, USA 3The Cancer Institute of New Jersey CINJ Rutgers, Inc, New Brunswick, NJ, USA 4Chesapeake Urology Research Associates, Towson, MD, USA 5Lifespan Oncology Clinical Research, Providence, RI, USA 6University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA

Tumor antigens | Biomarkers | Immune monitoring | T cell | Vaccine

P3

Persistence of 6-thioguanine-resistant T-cell clones in a melanoma patient with durable antitumor response following treatment with immune checkpoint blockade.

Cindy Zuleger1, Michael Newton1, Irene Ong1, Mark Albertini1,2

1Carbone Cancer Center at the University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 2William S. Middleton Memorial Veterans Hospital, Madison, WI, USA

Biomarkers | Checkpoint blockade | Immune monitoring | Solid tumors | T cell

P4

The prognostic and predictive roles of a CD8/PD-L1 signature in cancer

Sonja Althammer1, Keith Steele2, Moritz Widmaier1, Charles Brown2, Tze Heng Tan1, Lorenz Rognoni1, Hélène Kaplon3, David Friedrich1, Brandon W Higgs2, Günter Schmidt1, Koustubh Ranade2, Marie-Caroline Dieu-Nosjean3

1Definiens, Munich, Germany 2Medimmune, Gaithersburg, MD, USA 3INSERM, UMRS 1138, Paris, France

Checkpoint blockade | Biomarkers | Bioinformatics | Tumor microenvironment | Antibody | Clinical trial | Clinical study | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Chemotherapy

P5

Analytical Comparison of Methods Used to Assess Mismatch Repair Deficiency

Steven Anderson1, Li Cai2, Lori Johnson3, Bryan McCune2

1Covance, Durham, NC, USA 2Integrated Oncology, Research Triangle Park, NC, USA 3Covance, Morrisville, NC, USA

Biomarkers | Checkpoint blockade | Solid tumors

P6

Characterization of AB928, a Dual Adenosine A2aR/A2bR Antagonist That Retains Potency under Conditions of High Albumin and High Receptor Activation

Devika Ashok1, Lisa Seitz1, Joanne Tan1, Adam Park1, Tim Park1, Ferdie Soriano1, Terry Rosen1, Ehesan Sharif1, Dillon Miles1, Manmohan Leleti1, Juan Jaen1, Jay Powers1, Matthew Walters1, Steve Young1

1Arcus Biosciences, Hayward, CA, USA

Myeloid cells | Biomarkers | T cell | Tumor microenvironment

P7

Withdrawn




P8

T cell response profiling in colorectal carcinoma patients reveals an enrichment in responses to specific tumor-associated antigens

Kyle Ferber1, Johanna Kaufmann1, Christine McCoy1, Judy Jacques1, Abdulmohammad Pezeshki2, Ning Wu1, Michael O'Keefe1, Crystal Cabral1, Yana Ostrovsky1, Jason Dobson1, Theresa Zhang1, Pamela Carroll1, Khashayarsha Khazaie2, Jessica Flechtner1, Wendy Broom1

1Genocea Biosciences, Cambridge, MA, USA 2Mayo Clinic, Rochester, MN, USA

Biomarkers | Immune monitoring | Tumor antigens | T cell | Dendritic cell

P9

Using iPair-TCR™ and iPair-TCR+™ to track tumor infiltrating lymphocytes from peripheral blood in a longitudinal breast cancer patient study

Miranda Byrne-Steele1, Wenjing Pan1, Xiaohong Hou1, Brittany Brown1, Mary Eisenhower1, Alexa Fort1, Jian Han1

1iRepertoire Inc., Huntsville, AL, USA

Immune monitoring | T cell | Solid tumors | Gene expression | Tumor infiltrating lymphocytes (TILs) | CAR T cells

P10

Epithelial-mesenchymal transition (EMT) signature was inversely associated with activated CD8 infiltration in non-small cell lung cancer (NSCLC)

Young Kwang Chae1, Sangmin Chang1, Taeyeong Ko1, Jonathan Anker1, Sarita Agte2, Wade Iams1, Marcelo Cruz1

1Northwestern University Feinberg School of Medicine, Chicago, IL, USA 2Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

Immune suppression | Immunoscore | T cell | Tumor microenvironment | Biomarkers | Tumor infiltrating lymphocytes (TILs)

P11

WNT/β-catenin pathway is inversely correlated with activated CD8 T cell infiltration in non-small cell lung cancer(NSCLC).

Young Kwang Chae1, Taeyeong Ko1, Sangmin Chang1, Jonathan Anker1, Sarita Agte2, Wade Iams1, Marcelo Cruz1

1Northwestern University Feinberg School of Medicine, Chicago, IL, USA 2Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

Tumor microenvironment | Biomarkers | Immune suppression | Immunoscore | T cell | Tumor infiltrating lymphocytes (TILs)

P12

Precision Immune Monitoring: New 30-parameter Flow Cytometry Uniquely and Comprehensively Defines Immune Checkpoint Expression and T Cell Phenotypes in Tumor Tissue

Pratip Chattopadhyay1, Amber Giles2, Leonard Nettey3

1NYU Medical School, New York, NY, USA 2NIH, Bethesda, MD, USA 3VRC, NIH, Bethesda, MD, USA

Tumor microenvironment | Immune monitoring | Checkpoint blockade | Biomarkers | T cell | Tumor infiltrating lymphocytes (TILs)

P13

Pre-existing T-cell immunity, mutational burden and stromal TGF-β signaling drives clinical responses to atezolizumab in locally advanced or metastatic urothelial carcinoma (mUC)

Sanjeev Mariathasan1, Shannon J. Turley1, Dorothee Nickles1, Yulei Wang1, Edward E. Kadel III1, Hartmut Koeppen1, Kobe Yuen1, Allessandra Castiglioni1, Jillian L. Astarita1, Rafael Cubas1, Suchit Jhunjhunwala1, Romain Banchereau1, Yagai Yang1, Yinghui Guan1, Cecile Chalouni1, James Ziai1, Yasin Şenbabaoğlu1, Steve Lianoglou1, Michiel van der Heijden2, Yohann Loriot3, Johathan Rosenberg4, Lawrence Fong5, Ira Mellman1, Daniel S. Chen1, Marjorie Green1, Christina Derleth1, Gregg D. Fine1, Priti S. Hegde1, Richard Bourgon1, Thomas Powles6

1Genentech, Inc., South San Francisco, CA, USA 2Netherlands Cancer Institute, Amsterdam, Netherlands 3Gustave Roussy, Villejuif, France 4Memorial Sloan Kettering Cancer Center, New York, NY, USA 5University of California San Francisco, San Francisco, CA, USA 6Barts Experimental Cancer Medicine Centre, London, United Kingdom

Biomarkers | Gene expression | Checkpoint blockade | Clinical trial | Immune monitoring | Tumor microenvironment | Tumor stroma | Tumor infiltrating lymphocytes (TILs)

P14

Comprehensive characterization of solid tumor immune profiles for precision immunotherapy using Immune Report Card

Mary Nesline1, Jeffrey Conroy1, Sarabjot Pabla1, Ji He1, Blake Burgher1, Vicent Giamo1, Jonathan Andreas1, Paul DePietro1, Antonios Papanicolau-Sengos1, Mark Gardner1, Sean Glenn1, Carl Morrison1

1OmniSeq, Inc., Buffalo, NY, USA

Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Inflammation | Biomarkers | Immune monitoring | Gene expression | Solid tumors | T cell

P15

Overexpression of immunotherapeutic targets in the immune desert phenotype

Sarabjot Pabla1, Jeffrey Conroy1, Sean Glenn1, Ji He1, Blake Burgher1, Vincent Giamo1, Jonathan Andreas1, Maochun Qin1, Mark Gardner1, Antonios Papanicolau-Sengos1, Mary Nesline1, Carl Morrison1

1OmniSeq, Inc., Buffalo, NY, USA

Tumor microenvironment | Biomarkers | Checkpoint blockade | Immune monitoring | Gene expression | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P16

The immune activated phenotype: secondary immunotherapeutic targets in the primary biomarker negative inflamed tumor

Sean Glenn1, Jeffrey Conroy1, Sarabjot Pabla1, Ji He1, Blake Burgher1, Vincent Giamo1, Jonathan Andreas1, Mark Gardner1, Antonios Papanicolau-Sengos1, Mary Nesline1, Carl Morrison1

1OmniSeq, Inc., Buffalo, NY, USA

Tumor microenvironment | Biomarkers | Checkpoint blockade | Immune monitoring | Gene expression | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P17

The immune-excluded phenotype beyond colorectal cancer

Carl Morrison1, Sean Glenn1, Wiam Bshara2, Sarabjot Pabla1, Blake Burgher1, Vincent Giamo1, Jonathan Andreas1, Mary Nesline1, Mark Gardner1, Antonios Papanicolau-Sengos1, Igor Puzanov2, Marc Ernstoff2, Jeffrey Conroy1

1OmniSeq, Inc., Buffalo, NY, USA 2Roswell Park Cancer Institute, Buffalo, NY, USA

Tumor microenvironment | Biomarkers | Checkpoint blockade | Immune monitoring | Gene expression | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P18

Withdrawn




P19

Genomic determinants of response to pembrolizumab in gastric cancer

Razvan Cristescu1, Diane Levitan1, Julie Kobie1, Andrew Albright1, Ping Qiu1, Robin Mogg1, Jared Lunceford1, Xiao Qiao Liu1, Xinwei Sher1, Michael Nebozhyn1, Gladys Arreaza1, Wendy Blumenschein1, Mark Ayers1, Terrill McClanahan1, Andrey Loboda1, David Kaufman1, Rita Dalal1, Minori Koshiji1

1Merck & Co., Inc., Kenilworth, NJ, USA

Biomarkers | Checkpoint blockade | Gene expression | Solid tumors | Tumor microenvironment

P20

Distinct tumour immune profiles in non-small cell lung cancer (NSCLC) revealed by automated quantitative digital image analyses of immune biomarker densities and spatial relationships

Marie Cumberbatch1, Elaine Foster2, James Clay2, Sunita Mistry2, Andrew Lawrence2, Christopher Womack2, David Fairley2

1Immune Insight Limited, Macclesfield, United Kingdom 2HistologiX Limited, Nottingham, United Kingdom

Immune contexture | Tumor microenvironment | Biomarkers | Immune monitoring | Tumor infiltrating lymphocytes (TILs)

P21

Correlation of inflammatory biomarkers and patient-reported outcomes in patients with urothelial carcinoma treated with durvalumab

Arnold Degboe1, Srikala Sridhar2, Jingsong Zhang3, Pralay Mukhopadhyay1, Ashok Gupta1, Lorin Roskos1, Xiang Guo1, Terence Friedlander4

1AstraZeneca, Gaithersburg, MD, USA 2Princess Margaret Cancer Centre, Toronto, ON, Canada 3Moffitt Cancer Center, 12902 USF Magnolia Drive, FL, USA 4UCSF Medical Center, San Francisco, CA, USA

Biomarkers | Inflammation | Solid tumors | Clinical study

P22

Up-regulation of a T and NK cell gene signature in peripheral blood is associated with mRNA-based immunotherapy in lung and prostate cancer.

Henoch S Hong1, Madeleine M Hipp1, Fatma Doener1, James M Billingsley2, Linus Backert3, Oliver Kohlbacher3, Andreas Schröder1, Ute Klinkhardt1, Sabine Brutlach1, Uwe Peukert1, Ulrike Gnad-Vogt1, Mariola Fotin-Mleczek1, Sven D Koch1

1CureVac AG, 72076 Tübingen, Germany 2Emory University, Atlanta, GA, USA 3Applied Bioinformatics, University of Tübingen, 72076 Tübingen, Germany

Clinical trial | Immune monitoring | Tumor antigens | NK/NK T cell | T cell | Vaccine | Gene expression | Bioinformatics

P23

Deep molecular and immune-infiltrate stratification of cancer identifies mechanistic subtypes and predicts response to checkpoint inhibition.

Janusz Dutkowski1, Roy Ronen1

1Data4Cure, Inc., La Jolla, CA, USA

Bioinformatics | Checkpoint blockade | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Systems biology | Biomarkers

P24

Systematic Literature Review of PD-L1 Assays, Their Scoring Algorithms and Validation Metrics

Margarita Udall1, Maria Rizzo2, Juliet Kenny2, Jim Doherty1, Eric Faulkner3

1Pfizer Inc., New York, NY, USA 2Evidera, London, United Kingdom 3Evidera, Morrisville, NC, USA

Biomarkers | Checkpoint blockade | Solid tumors

P25

A Systematic Literature Review (SLR) of the predictive value of programmed death ligand 1 (PD-L1) tests on clinical outcomes

Margarita Udall1, Jim Doherty1, Amber Martin2, Juliet Kenney3, Eric Faulkner4, Pratibha Chander1, Paul Robbins1, SueAnn Dahm1

1Pfizer Inc., New York, NY, USA 2Evidera, Waltham, MA, USA 3Evidera, London, USA 4Evidera, Morrisville, NC, USA

Biomarkers | Checkpoint blockade | Solid tumors

P26

Certain KIR/KIR ligand genotypes influence patient response to immunotherapy in neuroblastoma patient

Amy K. Erbe1, Wei Wang1, Lakeesha Carmichael1, Anna Hoefges1, KyungMann Kim1, Wendy B. London2, Jacquelyn A. Hank1, Mitchell B. Diccianni3, Arlene Naranjo4, Michael D. Hogarty5, Julie R. Park6, Alice L. Yu7, Paul M. Sondel1

1University of Wisconsin-Madison, Madison, WI, USA 2Boston Children’s Hospital/Dana-Farber Cancer Institute, Boston, MA, USA 3University of California San Diego, San Diego, CA, USA 4University of Florida, Gainesville, FL, USA 5Children's Hospital of Philadelphia, Philadelphia, PA, USA 6Seattle Children's Hospital, Seattle, WA, USA 7University of California San Diego, San Diego, CA, USA

Genetic polymorphism | Pediatric tumors | Biomarkers | Clinical study | Immune toxicity | Targeted therapy | Tumor antigens | Antibody | Clinical trial | NK/NK T cell

P27

Optimized workflow improves the characterization of tumor-infiltrating T cells

Cesar Evaristo1, Ramona Siemer1, David Agorku1, Janina Brauner1, Olaf Hardt1, Christian Dose1, Anne Richter1

1Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

Tumor microenvironment | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Immune monitoring | Immune contexture | T cell lineages | Biomarkers

P28

Profiling of T cell responses to tumor-associated antigens in lung cancer patients treated with checkpoint inhibitors

Kyle Ferber1, Johanna K. Kaufmann1, Judy Jacques1, Christine McCoy1, Michael O'Keeffe1, Crystal Cabral1, Yana Ostrovsky1, Ning Wu1, Jason Dobston1, Theresa Zhang1, Pamela Carroll1, Jessica Flechtner1, Wendy Broom1

1Genocea Biosciences, Inc., Cambridge, MA, USA

T cell | Antigen presenting cells | Cytokine | Immune suppression | Immune monitoring | Checkpoint blockade | Biomarkers | Tumor antigens | Solid tumors | Vaccine

P29

Incorporating Premixed Staining Cocktail for Improving the Workflow for Whole Blood Immunophenotyping

Iliana Gonzalez1, Yoshinobu Koguchi1, William Miller1, Tanisha Meeuwsen1, Valerie K. Conrad1, Ana Howells-Ferreira1, Tomasz M. Poplonski1, William Redmond1

1Earle A. Chiles Research Institute, Portland, OR, USA

Immune monitoring | Antibody

P30

Mass spectrometry-based test predicts outcome on anti-PD-1 therapy for patients with advanced non-small cell lung cancer, including those with brain metastases

Sarah Goldberg1, Lucia Jilaveanu1, Harriet Kluger1, Veronica Chiang1, Amit Mahajan1, Bing Xia1, Matthew Ribeiro1, Heinrich Roder2, Joanna Roder2, Carlos Oliveira2, Julia Grigorieva2, Mirte Muller3, Anna-Larissa Niemeijer4, Robert Schouten3, Adrianus de Langen3,4, Egbert Smit3

1Yale School of Medicine, New Haven, CT, USA 2Biodesix, Steamboat Springs, CO, USA 3Netherlands Cancer Institute, Amsterdam, Netherlands 4VU University Medical Center, Amsterdam, Netherlands

Biomarkers | Checkpoint blockade | Proteomics | Solid tumors | Clinical trial

P31

Proteomic biomarker analysis of metastatic melanoma patients treated with anti-PD-1 checkpoint blockade

Paolo Antonio Ascierto1, Mariaelena Capone1, Antonio Maria Grimaldi1, Domenico Mallardo1, Ester Simeone1, Heinrich Roder2, Krista Meyer2, Senait Asmellash3, Carlos Oliveira2, Joanna Roder2

1Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy 2Biodesix, Steamboat Springs, CO, USA 3Biodesix, Boulder, CO, USA

Biomarkers | Checkpoint blockade | Proteomics | Solid tumors

P32

Differential association of myeloid cell and IFN-γ associated proteins with clinical response to durvalumab treatment in urothelial bladder cancer

Xiang Guo1, Wendy White1, Denise Jin2, Yanan Zheng2, Rajesh Narwal1, Yu Gu1, Ashok Gupta1, Pralay Mukhopadhyay3, Brandon Higgs1, Tony W. Ho3, Lorin Roskos1

1MedImmune, Gaithersburg, MD, USA 2MedImmune, Mountain View, CA, USA 3AstraZeneca, Gaithersburg, MD, USA

Biomarkers | Metabolism | Chemokine | Checkpoint blockade | Solid tumors

P33

The presence of effector immune cells in human CD200 positive tumor samples supports the CD200 immune checkpoint as a novel therapeutic target

Mark Hamilton1, Rui-Ru Ji2, Tony Arulanandam1, Sharon Barr1

1Alexion Pharmaceuticals, Inc., New Haven, CT, USA 2Alexion Pharmaceuticals, Inc., Lexington, MA, USA

Bioinformatics | Pediatric tumors | Biomarkers | Checkpoint blockade | Gene expression | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Proteomics | Tumor microenvironment

P34

Pre-existing anti-therapeutic antibodies against Fc-region determinants shared by rituximab and hu14.18K322A are associated with outcome in a phase I trial of hu14.18K322A

Jacquelyn Hank1, Jacob Goldberg1, Fariba Navid2, Amy Erbe1, Victor Santana3, Jacek Gan1, Fenna de Bie1, Amal Javaid1, Anna Hoefges1, Lakeesha Carmichael1, Michael Bishop3, Michael Meagher4, Stephen Gillies5, Janardan Pandey6, Paul Sondel1

1University of WI-Madison, Madison, WI, USA 2Children’s Hospital Los Angeles, Los Angeles, CA, USA 3St. Jude Children’s Research Hospital, Memphis, TN, USA 43St. Jude Children’s Research Hospital, Memphis, TN, USA 5Provenance Biopharmaceuticles, Carlisle, MA, USA 6Medical University of South Carolina, Charleston, SC, USA

Biomarkers | Clinical study | Immune monitoring | Targeted therapy | Antibody | Clinical trial | Vaccine

P35

Withdrawn

P36

Computational Tissue Analysis–Based Quantification of Tumor-Infiltrating Leukocytes Using Morphometrics in Immunohistochemistry Stained NSCLC Samples

Elliott Ergon1, Allison Harney1, Will Paces1, Kristin Wilson1, Karen Ryall1, Daniel Rudmann1, Brooke Hirsch1, Joseph Krueger1

1Flagship Biosciences, Westminster, CO, USA

Immune contexture | Inflammation | Tumor microenvironment | Biomarkers | Tumor infiltrating lymphocytes (TILs)

P37

Combining in situvaccination with checkpoint blockade enhances an endogenous anti-tumor B-cell response resulting in tumor-specific humoral memory

Clinton Heinze1, Claire Baniel1, Peter Carlson1, Jacquelyn Hank1, Raghava Sriramaneni1, Emily Guy1, Jasdeep Kler1, Sara Busche1, Stephen Gillies2, Hans Loibner3, Alan Korman4, Alexander Rakhmilevich1, Paul Sondel1, Zachary Morris1

1Wisconsin Institutes of Medical Research, Madison, WI, USA 2Provenance Biopharmaceuticals, Carlisle, MA, USA 3APEIRON Biologics, Vienna, Austria 4Bristol-Myers Squibb, Sunnyvale, CA, USA

B cell | Antibody | Biomarkers | Radiotherapy | Vaccine | Checkpoint blockade

P38

A Strategy to Assess Contributions of Individual Agents in Combination Immunotherapy Trials

Traci Hilton1, Christopher Paustian1, Yoshinobu Koguchi2, Adi Mehta3, Fridtjof Lund-Johansen4, Brian Boulmay, Rui Li, Kyle Happel, Tarsem Moudgil, Sachin Puri, Christopher Dubay, Brenda Fisher, Rogan Rattray, Mary Campbell

1Ubivac, Portland, OR, USA 2Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA 3Oslo, Norway 4Oslo University Hospital Rikshospitalet, Oslo, Norway

B cell | Antibody | Biomarkers | Clinical study | Immune monitoring | Proteomics | Tumor antigens | Vaccine | T cell | Clinical trial

P39

Use of ex vivo Histoculture to identify potential predictive biomarkers for the ICOS agonist antibody, JTX-2011

Heather Hirsch1, Jason Reeves1, Tong Zi1, Amit Deshpande1, Guang Yang1, Alexander Needham1, Jenny Shu1, Christopher Harvey1, Sriram Sathyanaryanan1, Jennifer Michaelson1, Emma Lees1, Elizabeth Trehu1, Debbie Law1

1Jounce Therapeutics, Inc., Cambridge, MA, USA

Biomarkers | Checkpoint blockade | Bioinformatics | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Regulatory T cell (Treg)

P40

Deep proteomic and transcriptomic analysis of sorted T cells with a simple, integrated workflow

Kit Fuhrman1, Douglas Hinerfeld1, Katherine Drake2, Gary Geiss1

1Nanostring Technologies, Inc., Seattle, WA, USA 2Cytobank, Inc., Santa Clara, CA, USA

T cell | Gene expression | Targeted therapy | Systems biology | Proteomics | Immune monitoring | Biomarkers | Regulatory T cell (Treg)

P41

IgG antibodies correspond with T cell responses to tumor neoantigens

Tyler Hulett1, Shawn Jensen1, Larry David2, Ashok Reddy2, Phillip Wilmarth2, Carmen Ballesteros-Merino1, Christopher Dubay1, Michael Afentoulis1, Bernard Fox1

1Earle A. Chiles Research Institute, Portland, OR, USA 2Oregon Health & Science University, Portland, OR, USA

T cell | Antibody | Vaccine | Tumor antigens | Proteomics | Neoantigens | Autoimmunity | Biomarkers | Bioinformatics

P42

The checkpoint inhibitor TTI-621 (SIRPαFc) stimulates innate and adaptive immune responses in patients with hematologic and solid tumor malignancies

Lisa Johnson1, Stephen Ansell2, Robert Chen3, Ian Flinn4, Michael Maris5, Owen O'Connor6, Alexander Lesokhin7, John Thompson8, Oleg Akilov9, Christiane Querfeld3, Matthew Taylor10, Meghan Irwin1, Tina Catalano1, Penka Petrova1, Eric Sievers1, Robert Uger1

1Trillium Therapeutics Inc., Mississauga, ON, Canada 2Mayo Clinic, Rochester, MN, USA 3City of Hope, Duarte, CA, USA 4Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA 5Sarah Cannon Research Institute/Colorado Blood Cancer Institute, Denver, CO, USA 6Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA 7Memorial Sloan Kettering Cancer Center, New York, NY, USA 8University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA 9University of Pittsburgh, Pittsburgh, PA, USA 10Oregon Health and Science University, Portland, OR, Canada

Biomarkers | Checkpoint blockade | Immune monitoring | Clinical trial | Cytokine | Monocyte/Macrophage | T cell | Chemokine | Solid tumors

P43

Assessment of Pharmacodynamic Effects of Immuno-Oncology Agents in Cynomolgus Monkeys using High-Content Gene Expression Profiling

Veena Kandaswamy1, Amelie Forest1, Thompson Doman2, Manisha Brahmachary1, Krishna Chodavarapu1, Jason Manro2, John Rhoden2, Bing Han2, Nate Elliott3, Sarah Warren3, Tim Riordan3, Christina Bailey3, Ruslan Novosiadly1, Michael Kalos1, Gerald Hall1

1Eli Lilly & Company, New York, NY, USA 2Eli Lilly & Company, Indianapolis, IN, USA 3NanoString Technologies, Seattle, WA, USA

Biomarkers | Antibody | Monocyte/Macrophage | T cell | Gene expression

P44

Patient selection strategies and pharmacodynamic assays for CCR4 antagonists

Abood Okal1, William Ho1, Brian Wong1, Paul Kassner1, Gene Cutler1

1FLX Bio Inc., South San Francisco, CA, USA

Bioinformatics | Regulatory T cell (Treg) | Immune suppression | Gene expression | Chemokine | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Biomarkers

P45

The inhibitory checkpoint molecule NKG2A is upregulated on tumor infiltrating NK cells and CD8 T cells in human head and neck tumors

Michael Korrer1, Young Kim1

1Vanderbilt University Medical Center, Nashville, TN, USA

Tumor microenvironment | T cell | NK/NK T cell | Immune suppression | Checkpoint blockade

P46

The impact of anti-PD-1 treatment on the immune cells and their correlation with the circulating tumour cells in patients with non-small cell lung cancer

Eleni-Kyriaki Vetsika1, Despoina Aggouraki1, Galaktia Kallergi1, Zaharoula Lyristi1, Aristeidis Koukos1, Despoina Kourougkiaouri1, Konstantinos Rounis2, Vassilis Georgoulias1, Athanasios Kotsakis2

1University of Crete, Faculty of Medicine, Heraklion, Greece 2University General Hospital of Heraklion, Crete, Greece, Heraklion, Greece

Biomarkers | Checkpoint blockade | Immune monitoring | Solid tumors

P47

Gene expression analysis of IL-13Rα2 in human adrenocortical carcinoma correlates with poor survival

Abhinav Kumar1, Ian Bellayr1, Raj Puri1

1Food and Drug Administration, Silver Spring, MD, USA

Bioinformatics | Biomarkers | Gene expression

P48

Different impact of immune cell infiltration and HLA class I expression in lymph node vs. cutaneous/subcutaneous metastases as predictive markers in melanoma patients treated with ipilimumab

Tímea Balatoni1, Anita Mohos2, Eszter Papp1, Tímea Sebestyén3, Gabriella Liszkay1, Judit Oláh4, Anita Varga4, Zsuzsanna Lengyel5, Gabriella Emri6, Soldano Ferrone7, Andrea Ladányi1

1National Institute of Oncology, Budapest, Hungary 2Semmelweis University, Budapest, Hungary 3St. John's Hospital, Budapest, Hungary 4Albert Szent-Györgyi Medical Center, University of Szeged, Szeged, Hungary 5University of Pécs, Pécs, Hungary 6Faculty of Medicine, University of Debrecen, Debrecen, Hungary 7Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Immune contexture | Tumor microenvironment | Biomarkers | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs)

P49

Characterization of immune checkpoint marker expression and infiltrating lymphoid and myeloid immune cells in the tumor microenvironment by RNA in situ hybridization

Annelies Laeremans1, Na Li1, Jeffrey Kim1, Xiao-Jun Ma1, Emily Park1

1Advanced Cell Diagnostics, Newark, CA, USA

Myeloid cells | Regulatory T cell (Treg) | T cell lineages | Tumor microenvironment | Checkpoint blockade | Biomarkers | Immune monitoring | Gene expression | Cytokine | Tumor infiltrating lymphocytes (TILs)

P50

Application of the immunoscore as prognostic biomarkers in patients with epithelial ovarian cancer

Shin-Wha Lee1, Hee Jung Jung1, Young-Jae Lee1, Ha-Young Lee2, Yong-Man Kim1, Young-Tak Kim1

1Ulsan University, ASAN Medical Center, Seoul, Republic of Korea 2ASAN Institute for Life Science, Seoul, Republic of Korea

Immune monitoring | Immunoscore | Immune contexture | Biomarkers

P51

FGFR2b expression and baseline immune signature to guide FPA144 development in urothelial cancer

Yeonju Lee1, Nerissa Mendoza1, Janine Powers1, Lee Clark1, James Hnatyszyn1, Carmen Ladner1, Helen Collins1, Kevin P. Baker1, Majid Ghoddusi1

1Five Prime Therapeutics, Inc., South San Francisco, CA, USA

Tumor microenvironment | Biomarkers | Immune monitoring | Solid tumors | Tumor infiltrating lymphocytes (TILs)

P52

Partially exhausted T lymphocyte directed neoadjuvant immunotherapy in unresectable Stage III melanoma

Lauren Levine1, Clinton Wu1, Kelly Mahuron1, Katy Tsai1, Alain Algazi1, Michael Rosenblum1, Michael Alvarado1, Adil Daud1

1Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA

Biomarkers | Checkpoint blockade | Clinical study | T cell | Solid tumors | Tumor infiltrating lymphocytes (TILs)

P53

The crosstalk between PD-1, CD137 and OX40 in head and neck cancer

Robert Ferris1

1UPCI, Pittsburgh, PA, USA

Antibody | Biomarkers | Costimulation | Coinhibition | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment

P54

Multiplex IHC Immuno-Oncology Panel for standardized profiling of the immune status based on spatial and functional characterization of the tumor microenvironment

Svenja Lippok1, Florian Leiss1, Katrin Schneider1, Tobias Wiestler1, René Korn1, Dasa Medrikova1, Moritz Widmaier1, Martin Hager1, Ivan Kanchev1, Anthony Masci2, Gela Sia2, Chris Kerfoot2, Lisa Dauffenbach2, Ralf Huss1

1Definiens AG, 80636 Munich, Germany 2Mosaic Laboratories, Lake Forest, CA, USA

Bioinformatics | Tumor microenvironment | Biomarkers | Immunoscore | Immune tolerance | Immune contexture | Inflammation | Checkpoint blockade | Systems biology | Tumor stroma

P55

Non-fucosylated anti-CTLA-4 antibody enhances vaccine-induced T-cell responses in a non-human primate pharmacodynamic vaccine model

John Loffredo1, Raja Vuyyuru1, Vanessa Spires1, Sophie Beyer1, Maxine Fox1, Jon Ehrmann1, Katrina Taylor1, John Engelhardt1, Alan Korman1, Robert Graziano1

1Bristol-Myers Squibb, Princeton, NJ, USA

Biomarkers | Checkpoint blockade | Vaccine | T cell | Immune adjuvant | Immune monitoring

P56

Widespread human T cell receptor variable gene polymorphism revealed by long amplicon TCRβ repertoire sequencing: Implications for the prediction and interpretation of immunotherapy outcome

Tim Looney1, Alex Glavin1, Sarabjot Pabla2, Sean Glenn2, Lauren Miller3, Denise Topacio-Hall3, Elizabeth Linch3, Alice Zheng1, Jeffrey Conroy2, Blake Burgher2, Carl Morrison2, Geoffrey Lowman3, Mark Andersen3, Fiona Hyland1

1Thermo Fisher Scientific, South San Francisco, CA, USA 2OmniSeq, Buffalo, NY, USA 3Thermo Fisher Scientific, Carlsbad, CA, USA

Tumor microenvironment | Genetic polymorphism | Adoptive immunotherapy | Autoimmunity | Checkpoint blockade | Immune monitoring | Neoantigens | T cell | Tumor infiltrating lymphocytes (TILs)

P57

Insights into the tumor microenvironment and therapeutic T cell manufacture revealed by long amplicon immune repertoire sequencing

Geoffrey Lowman1, Tim Looney2, Elizabeth Linch1, Lauren Miller1, Denise Topacio-Hall1, Alex Pankov2, Alice Zheng2, Reidun Hartberg3, Hilde Almåsbak3, Tor Espen Stav-Noraas3, Anette Kullmann3, Fiona Hyland2, Mark Andersen1

1Thermo Fisher Scientific, Carlsbad, CA, USA 2Thermo Fisher Scientific, South San Francisco, CA, USA 3Thermo Fisher Scientific, Oslo, Norway

Adoptive immunotherapy | T cell lineages | Tumor microenvironment | Tumor antigens | Immune monitoring | Biomarkers | Autoimmunity | CAR T cells | Gene expression | T cell

P58

Public NY-ESO-1 specific TCRs as novel biomarkers for immune monitoring of NY-ESO-1 positive cancer patients

Hailing Lu1, Seth Pollack2, Neeta Somaiah3, Sant Chawla4, Patrick Hwu3, Marissa Vignali5, Julie Rytlewski5, Sacha Gnjatic6, Jan ter Meulen1

1Immune Design, Seattle, WA, USA 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA 3MD Anderson Cancer Center, Houston, TX, USA 4Santa Monica Oncology Center, Santa Monica, CA, USA 5Adaptive Biotechnologies, Seattle, WA, USA 6Icahn School of Medicine at Mount Sinai, New York, NY, USA

Immune monitoring | Biomarkers | Vaccine | Tumor antigens | Clinical study | Clinical trial

P59

Multi color flow cytometry comparative analysis with DA-Cell(TM) centrifugation-less washing

Xavier Le Guezennec, Ph.D.1

1Curiox Biosystems, San Carlos, CA, USA

Biomarkers | Antibody | Systems biology

P60

Comparative Study of Flow Cytometry Analysis between Conventional Centrifuge Method and Centrifuge-less DA-Cell™ Method from the Perspective of Cell Retention

Xavier Le Guezennec1

1Curiox Biosystems, San Carlos, CA, USA

Inflammation | Autoimmunity | Antibody | Immune suppression | Immune monitoring | Biomarkers

P61

Cellular and genomic disease signature of peripheral blood mononuclear cells in patients with malignant pleural mesothelioma

Zachary R. Mallon1, Christophe Poulet1, Amanda Enstrom1, Somayeh Honarmand1, Aimee L. Murphy1, Raffit Hassan2, Dirk G. Brockstedt1, Chan C. Whiting1, Nitya Nair1

1Aduro Biotech, Inc., Berkeley, CA, USA 2National Cancer Institute, Bethesda, MD, USA

Biomarkers | Immune monitoring | Clinical trial | Gene expression

P62

Circulating T cell Subpopulations Correlate with Immune Inflammatory Signatures at the Tumor Site in Melanoma and Non-Squamous Non-small Cell Lung Cancer

Nataly Manjarrez-Orduño1, Selena Kansal1, Laurence Menard1, Sergey Lezhnin2, Can Jiang1, Paul Kayne1, Robin Edwards1, Suzanne Suchard1, Paul Fischer1, Bijal Kakrecha1, Chiang Yu1, Julie Carman1, Hongyue Dai2, Steven Bernstein1, Steven Nadler1

1Bristol-Myers Squibb, Princeton, NJ, USA 2M2GEN, Tampa, FL, USA

Immune contexture | T cell lineages | Biomarkers | Checkpoint blockade | Immune monitoring | Targeted therapy | T cell | Tumor microenvironment | Clinical study | Gene expression

P63

Measurement of the immune-suppressor nitric oxide within immune cell subsets in patients receiving ipilimumab with a peptide vaccine

Isaac P. Foote1, Zhihua Chen1, Y. Ann Chen1, Adam W. Mailloux1, Alisha Agrawal1, Braydon J. Schaible1, Amod Sarnaik1, Jeffrey S. Weber2, Anders E. Berglund1, James J. Mulé1, Joseph Markowitz1

1Moffitt Cancer Center, Tampa, FL, USA 2NYU, New York, NY, USA

Bioinformatics | Checkpoint blockade | Biomarkers | Immune monitoring

P64

Analytical Validation of Digital Spatial Profiling - a novel approach for multiplexed characterization of protein distribution and abundance in FFPE tissue sections

Kristi Barker1, Heather Metz1, Chris Merritt1, Lucas Dennis1, Philippa Webster1, Joseph Beechem1

1NanoString Technologies, Inc., Seattle, WA, USA

Tumor microenvironment | Tumor stroma | Tumor antigens | Tumor infiltrating lymphocytes (TILs) | T cell | Antibody | Solid tumors | Biomarkers

P65

Spatially-resolved, multiplexed digital characterization of protein abundance in FFPE tissue sections: application in preclinical mouse models

Yan Liang1, Alison VanSchoiack1, JingJing Gong1, Chris Merritt1, Dwayne Dunaway1, Jaemyeong Jung1, Isaac Sprague1, Sarah Warren1, Joseph Beechem1

1NanoString Technologies Inc., Seattle, WA, USA

Regulatory T cell (Treg) | T cell lineages | Tumor microenvironment | Biomarkers | Tumor antigens | Tumor stroma | Antibody | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)

P66

Digital spatial profiling platform allows both spatially-resolved, multiplexed measurement of solid tumor and immune-associated protein distribution and abundance using a single FFPE tissue section

Youngmi Kim1, Chris Merritt1, Giang Ong1, Kristi Barker1, Jaemyeong Jung1, Isaac Sprague1, Yan Liang1, Sarah Warren1, Philippa Webster1, Dwayne Dunaway1, Joseph Beechem1

1NanoString Technologies Inc., Seattle, WA, USA

Regulatory T cell (Treg) | T cell lineages | Tumor microenvironment | Antibody | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Tumor stroma | Tumor antigens | Biomarkers

P67

Standardization of tumor infiltrating lymphocytes isolation for flow cytometric analysis

William Miller1, Yoshinobu Koguchi1, William Redmond1

1Earle A. Chiles Research Institute, Portland, OR, USA

Tumor infiltrating lymphocytes (TILs) | Immune monitoring

P68

Immunogenomic evolution and atypical response to atezolizumab in a patient with metastatic triple-negative breast cancer (mTNBC)

Luciana Molinero1, Yijin Li1, Ching-Wei Chang1, Sophia Maund1, Maureen Berg2, Jeanne Harrison2, Marcella Fassò1, Carol O’Hear1, Priti S. Hegde1, Leisha A. Emens3

1Genentech, Inc., South San Francisco, CA, USA 2Johns Hopkins School of Medicine, Baltimore, MD, USA 3Johns Hopkins University School of Medicine, Baltimore, MD, USA

Biomarkers | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | Tumor stroma | Tumor microenvironment | Immune monitoring | Clinical study | Gene expression

P69

A pan-cancer diagnostic, prognostic and targetable biomarker pipeline defining the failed immune-response

Anne Monette1,2, Antigoni Morou1,2, Louise Rousseau2, Jean-Baptiste Lattouf1, Daniel Kaufmann1, Igor Jurisica3, Rejean Lapointe1,2

1University of Montreal, Montreal, QC, Canada 2CRCHUM, Montreal, QC, Canada 3University of Toronto / 7Princess Margaret Cancer Centre and Techna, Toronto, ON, Canada

T cell | B cell | Bioinformatics | Biomarkers | Systems biology | Gene expression | Immune tolerance | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Immune monitoring

P70

Halioseek™, a dual CD8 and PD-L1 IVD assay to improve NSCLC patients stratification

Florence Monville1, Emmanuel Prestat1, Laurent Vanhille1, Julien Adam2, Sergiu Coslet3, Caroline Laugé1, Caroline Davin1, Merle Sophie Losch1, Luciana Batista1, Jacques Fieschi1

1HalioDx, Marseille, France 2Gustave Roussy Cancer Campus, Villejuif, France 3MImAbs, Marseille, France

Immune contexture | Tumor microenvironment | Biomarkers | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | Solid tumors | T cell | Antibody

P71

Peptide-induced whole blood gene expression analysis for peptide-specific T-cell response

Taku Murakami1, Keiji Dohi2, Kenji Kuwabara2, Mieko Ogura1, Masato Mitsuhashi1

1Hitachi Chemical Co. America, Ltd., Irvine, CA, USA 2Shionogi & Co., Ltd., Osaka, Japan

Biomarkers | T cell | Vaccine | Gene expression

P72

Analysis of biomarkers from a cohort of advanced melanoma patients previously exposed to immune checkpoint inhibition treated with entinostat (ENT) and pembrolizumab (PEMBRO)

Melissa L. Johnson1, Dmitry Gabrilovich2, Fang Wang2, Rene Gonzalez3, Mateusz Opyrchal4, David Tamang5, Emmett Schmidt6, Michael L. Meyers7, Peter Ordentlich5, Sanjiv S. Agarwala8

1Sarah Cannon Research Institute, Nashville, TN, USA 2The Wistar Institute, Philadelphia, PA, USA 3University of Colorado Comprehensive Cancer Center, Aurora, CO, USA 4Roswell Park Cancer Institute, Buffalo, NY, USA 5Syndax Pharmaceuticals, Inc., Waltham, MA, USA 6Merck & Co., Inc., Kenilworth, NJ, USA 7Syndax Pharmaceuticals, Inc., New York, NY, USA 8St. Luke’s Cancer Center and University Health Network, Easton, PA, USA

Immune monitoring | Immune suppression | Checkpoint blockade | Clinical study | Clinical trial | Inflammation | Myeloid cells | Tumor microenvironment | Biomarkers | MDSC

P73

First-in-human neoadjuvant study of the immunogenomic impact of the oral IDO inhibitor epacadostat (INCB024360) on the tumor microenvironment of advanced ovarian cancer.

Junko Matsuzaki1, Amit Lugade1, Wiam Bshara1, Katherine Collins1, Sarah Warren2, Patrick Danaher2, Lucas Dennis2, Antonios Papanicolau-Sengos1, Leonard D’Amico3, Nirasha Ramchurren3, Angela Omilian1, Kevin Eng1, Sebastiano Battaglia1, Robert Newton4, Peggy Scherle4, Lance Leopold4, Steven Fling3, Richard Shine3, Martin Cheever3, Melissa Geller5, Kunle Odunsi1

1Roswell Park Cancer Institute, Buffalo, NY, USA 2Nanostring, Seattle, WA, USA 3CITN, Seattle, WA, USA 4Incyte Corporation, Wilmington, DE, USA 5University of Minnesota, Minneapolis, MN, USA

Biomarkers | Immune monitoring | Tumor microenvironment | Immune suppression | Gene expression

P74

Increasing the levels of anti-beta glucan antibodies by administration of intravenous immunoglobulin (IVIG) induces immunopharmacodynamic (IPD) responses of a novel immunotherapeutic Imprime PGG

Nadine Ottoson1, Keith Gorden1, Blaine Rathmann1, Xiaohong Qiu1, Ben Harrison1, Michele Gargano1, Nandita Bose1, Gautam Jha2, Arkadiusz Dudek3

1Biothera Pharmaceuticals, Eagan, MN, USA 2The University of Minnesota, Minneapolis, MN, USA 3HealthPartners Institute, St. Paul, MN, USA

Biomarkers | Clinical study | Monocyte/Macrophage | Immune monitoring

P75

iSEND Is an Algorithmic Model Specific for Advanced Non-Small Cell Lung Cancer Patients Treated with PD-1 / PD-L1 Inhibitors

Wungki Park1, Vaia Florou1, Sandra Algaze1, Diana Saravia1, Deukwoo Kwon1,2, Gilberto Lopes1

1University of Miami Miller School of Medicine, Miami, FL, USA 2Sylvester Comprehensive Cancer Center, Miami, FL, USA

Biomarkers | Checkpoint blockade | Myeloid cells | Clinical study

P76

Usefulness of automated multidimensional flow cytometry analyses for monitoring the status of T and APC compartments in breast cancer patients under neoadjuvant chemotherapy

David Bernal-Estévez1, Carlos Parra-López2

1Fundación Salud de los Andes, Bogota, Colombia 2Universidad Nacional de Colombia, Bogota, Colombia

Antigen presenting cells | Bioinformatics | Chemotherapy | Dendritic cell | Immune contexture | Biomarkers | Immune monitoring | T cell

P77

The Novel IL-2 Cytokine Immune Agonist NKTR-214 Harnesses the Adaptive and Innate Immune System for the Treatment of Solid Cancers

Salah Eddine Bentebibel1, Chantale Bernatchez1, Cara Haymaker1, Michael Hurwitz2, Patrick Hwu1, Mario Sznol2, Nizar Tannir1, Sandra Aung3, Michael Imperiale3, Mary Tagliaferri3, Christie Fanton3, Ernesto Iacucci3, Jonathan Zalevsky3, Ute Hoch3, Adi Diab1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2Yale School of Medicine, New Haven, CT, USA 3Nektar Therapeutics, San Francisco, CA, USA

Solid tumors | Tumor infiltrating lymphocytes (TILs) | Cytokine | Regulatory T cell (Treg) | Biomarkers | Tumor microenvironment | Gene expression | Clinical trial | Immune monitoring | T cell

P78

Immune, molecular and T cell repertoire landscape of 235 resected non-small cell lung cancers, paired normal lung and peripheral blood mononuclear cells

Alexandre Reuben1, Rachel Gittelman2, Jiexin Zhang1, Runzhe Chen1, Kelly Quek1, Luis Vence1, Irina Fernandez-Cubelo1, Carmen Behrens1, Jianjun Gao1, Erik Yusko3, Ryan Emerson3, Sharon Benzeno3, Marissa Vignali3, Christopher Tipton4, Ali Jalali1, Won-Chul Lee1, Jun Li1, Xifeng Wu1, Yuanqing Ye1, Agda Eterovic1, Latasha Little1, Curtis Gumbs1, Vancheswaran Goplakarishnan1, Chantale Bernatchez1, Cara Haymaker1, Marie-Andrée Forget1, Lorenzo Federico1, Tina Cascone1, Harlan Robins5, Emily Roarty1, Jaime Rodriguez1, Edwin Parra1, Jennifer Wargo1, James Allison1, Padmanee Sharma1, Jianhua Zhang1, Jack Lee1, Boris Sepesi1, Stephen Swisher1, Don Gibbons1, John Heymach1, Andy Futreal1, Ignacio Wistuba6, Jianjun Zhang6

1MD Anderson Cancer Center, Houston, TX, USA 2Adaptive Biotechnologies, Seattle, WA, USA 3Adaptive Technologies, Seattle, WA, USA 4Emory University School of Medicine, Atlanta, GA, USA 5MD Anderson Cancer Center, Seattle, WA, USA 6MD Anderson, Houston, TX, USA

Adoptive immunotherapy | Immune contexture | Tumor infiltrating lymphocytes (TILs) | T cell | Immune monitoring

P79

T-cell inflamed gene expression profile (GEP) analysis of pembrolizumab- and ipilimumab-treated patients with advanced melanoma in the multicenter, randomized, open-label phase 3 KEYNOTE-006 study

Antoni Ribas1, Caroline Robert2, Jacob Schachter3, Georgina Long4, Ana Arance5, Jean-Jacques Grob6, Matteo Carlino7, James Larkin8, Andrea Webber9, Robin Mogg9, Mark Ayers9, Jared Lunceford9, Fang Liu9, Michael Nebozhyn9, Andrew Albright9, Wendy Blumenschein9, Clemens Krepler9, David Kaufman9, Nageatte Ibrahim9, Adil Daud10

1University of California, Los Angeles, Los Angeles, CA, USA 2Gustave Roussy and Paris-Sud University, Villejuif, France 3Ella Lemelbaum Institute for Melanoma, Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel 4Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital, Sydney, Australia 5Hospital Clinic de Barcelona, Barcelona, Spain 6Aix Marseille University, Hôpital de la Timone, Marseille, France 7Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Blacktown, Australia 8Royal Marsden Hospital, London, United Kingdom 9Merck & Co., Inc., Kenilworth, NJ, USA 10University of California, San Francisco, San Francisco, CA, USA

Antibody | Biomarkers | Checkpoint blockade | Clinical trial | Clinical study | Gene expression | Solid tumors | Targeted therapy | T cell | Tumor microenvironment

P80

Testing Systems Immune Monitoring by Mass Cytometry for Clinical Correlative Research

Caroline Roe1, Allison Greenplate1, Jonathan Irish1

1Vanderbilt University, Nashville, TN, USA

Systems biology | T cell | Immune monitoring | Biomarkers | Checkpoint blockade | Targeted therapy

P81

The immunomodulatory effects of cancer therapy on IFN-gamma responses in the periphery

Laura Rosa Brunet1, James Crooks2, Andrew MacDonald2, Samuel LaBrie3, Dominic Eisinger3

1Immodulon Therapeutics Ltd, Uxbridge, United Kingdom 2Manchester University, Manchester, United Kingdom 3Myriad RBM, Austin, TX, USA

Biomarkers | Immune monitoring | Immune adjuvant | Dendritic cell | T cell

P82

Potential biomarkers in mRCC patients treated with nivolumab

Maria Sayapina1, Dmitry Nosov2, Nikita Savelov3, Nina Lyubimova1, Yuriy Timofeev1

1N.N. Blokhin Russian Oncology Research Center, Moscow, Russian Federation 2The Central Clinical Hospital for Presidential Affairs, Moscow, Russian Federation 3The Moscow City Oncology Hospital No. 62, Istra, Russian Federation

Biomarkers | Checkpoint blockade | Solid tumors

P83

Characterizing Cancers by Prevalence on the PD-L1/CD8 Axis

Guenter Schmidt1, Keith Steele2, Armin Meier1, Thomas Herz1, Tze Heng Tan1, Brandon Higgs2, Sonja Althammer1, Ralf Huss1

1Definiens AG, Munich, Germany 2MedImmune LLC, Gaithersburg, MD, USA

Immune contexture | Bioinformatics | Immunoscore | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Biomarkers | Tumor microenvironment | Solid tumors

P84

Relevance of the microenvironment and MHC class I mediated immune escape mechanisms of tumors for anti-tumoral immune responses

Barbara Seliger1

1Institute of Medical Immunology, Halle, Germany

Tumor microenvironment | Immune contexture | Tumor evasion | Immune monitoring | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Immune suppression | Immunoscore | T cell | Biomarkers

P85

HAAH and MMP9 are Complementary Cancer Biomarkers and Together Potentially Enhanced Predictors of Metastasis

Mark Semenuk1, Eleanor Ghanbari1, Anokhi Cifuentes1, Anjali Kalra1, Michael Lebowitz1, Hossein Ghanbari1

1Panacea Pharmaceuticals Inc, Gaithersburg, MD, USA

Biomarkers | Tumor antigens | Tumor microenvironment | Tumor evasion

P86

Altered immune cell repertoire and activity after checkpoint blockade immunotherapy with nivolumab in renal cell carcinoma

Michael Staehler1, Chiara Massa2, Annabel Spek1, Daniel Bethmann2, Jurgen Bukur2, Anja Mueller2, Claudia Wickenhauser2, Bernard A. Fox3, Barbara Seliger2

1Ludwig Maximilian University, Munich, Germany 2Martin Luther University, Halle, Germany 3Robert W. Franz Cancer Research Center, Portland, OR, USA

Biomarkers | Checkpoint blockade | Solid tumors

P87

Results of epigenetic-based quantitative PCR assisted immune cell counting analysis in bavituximab SUNRISE trial subgroup

Nikoletta L. Kallinteris1, Thomas O. Kleen2, Min Tang1, Shen Yin1, Tobi Guennel3, Jennifer Lai1, Victor Nowakowski2, Steven Olek2, Steve King1, Joseph S. Shan1

1Peregrine Pharmaceuticals, Tustin, CA, USA 2Epiontis GmbH, Berlin, Germany 3Precision Medicine, Frederick, MD, USA

Biomarkers | Clinical trial | Antibody | Monocyte/Macrophage | MDSC | Checkpoint blockade | Immune suppression | T cell | NK/NK T cell | Regulatory T cell (Treg)

P88

CD96, a new candidate for checkpoint blockade in human hepatocellular carcinoma

Zhigang Tian1, Cheng Sun1

1Institute of Immunology, The Key Laboratory of Innate Immunity and Chronic Disease (Chinese Academy of Medical Science), School of Life Sciences and Medical Center, University of Science & Technology of China, hefei, China

Checkpoint blockade | Immune tolerance | NK/NK T cell | Tumor infiltrating lymphocytes (TILs)

P89

Plasma-derived exosomes carrying CTLA-4, PD-1 and PD-L1 in head and neck squamous cell carcinoma patients treated with immunotherapy is associated with disease outcome

Marie-Nicole Theodoraki1, William E. Gooding2, Robert L. Ferris1, Theresa L. Whiteside1

1University of Pittsburgh, Pittsburgh, PA, USA 2Hillman Cancer Center, Pittsburgh, PA, USA

Immune monitoring | Clinical trial | Checkpoint blockade

P90

RNA-based immune gene set signatures demonstrate immune modulation by RXDX-106, a novel TAM (TYRO3, AXL, MER) family small molecule kinase inhibitor

Elizabeth Tindall1, Heather Ely1, Yumi Yokoyama1, Colin Walsh1, Erin Lew1, Amy Diliberto1, Robin Nevarez1, Jack Lee1, Ian Silverman1, Joanne Oh1, Gary Li1, Amanda Albert1, Jason Christiansen1, Robert Shoemaker1

1Ignyta, San Diego, CA, USA

Bioinformatics | Tumor microenvironment | Biomarkers | Immunoscore | Gene expression | Immune monitoring

P91

A harmonized evaluation system for expression of HLA class I antigens in formalin-fixed paraffin embedded cancer tissues

Toshihiko Torigoe1, Nobuyoshi Hiraoka2, Naoya Nakamura3, Eri Atsuyama4, Shingo Toji5, Yuji Heike4

1Sapporo Medical University School of Medicine, Sapporo, Japan 2National Cancer Center Hospital, Tokyo, Japan 3Tokai University School of Medicine, Isehara, Japan 4St Luke’s International University, Tokyo, Japan 5Medical Biological Laboratories Co., Ltd., Ina, Japan

Immune tolerance | Tumor microenvironment | Biomarkers | Immune monitoring | Tumor antigens | Immunoscore | Solid tumors | Tumor evasion

P92

Early Biomarker Correlates of Severe Neurologic Events and Cytokine Release Syndrome in ZUMA-1, A Multicenter Trial Evaluating Axicabtagene Ciloleucel in Refractory Agressive Non-Hodgkin Lymphoma

Frederick Locke1, Marika Sherman2, John Rossi2, Allen Xue2, Michelle Mojadidi2, Sattva Neelapu3, Armin Ghobadi4, Lazaros Lekakis5, David Miklos6, Caron Jacobson7, Olalekan Oluwole8, Tanya Siddiqi9, Yi Lin10, Patrick Reagan11, William Go2, Jeff Wiezorek2, Adrian Bot2

1Moffitt Cancer Center, Tampa, FL, USA 2Kite Pharma, Santa Monica, CA, USA 3The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4Washington University School of Medicine, Saint Louis, MO, USA 5University of Miami Health System, Sylvester Comprehensive Care Center, Miami, FL, USA 6Stanford University School of Medicine, Stanford, CA, USA 7Dana-Farber Cancer Institute, Boston, MA, USA 8Vanderbilt-Ingram Cancer Center, Nashville, TN, USA 9City of Hope National Medical Center, Duarte, CA, USA 10Mayo Clinic, Rochester, MN, USA 11University of Rochester Medical Center,, Rochester, MN, USA

Antigen presenting cells | Biomarkers | CAR T cells | Leukemia/Lymphoma | T cell | Adoptive immunotherapy | Immune contexture | Inflammation

P93

Small molecule binders of Ly6K inhibit tumorigenic growth and induce immunity via TGFb/Stat1 and PDL1 pathway

Megha Kumar1, Jinya Chen1, Idalia Cruz1, Purushottam Tiwari1, Aykut Uren1, Maksymilian Chruszcz2, Michael B. Atkins1, Louis M. Weiner1, Geeta Upadhyay1

1Lombardi Comprehensive Cancer Center, Georgetown University Medical center, Washington, DC, USA 2Lombardi Comprehensive Cancer Center, Georgetown University Medical center, Columbia, SC, USA

Tumor microenvironment | Stem cell/cancer-initiating cell | Biomarkers | Immune monitoring | Carcinogenesis | Solid tumors | Checkpoint blockade

P94

The RareCyte® platform for identifying rare antigen-specific circulating CD4 and CD8 T cells in Merkel cell carcinoma

Lance U'Ren1, Natalie Vandeven2, Erika Hayes3, Jennifer Chow1, Jackie Stilwell1, Paul Nghiem2, Eric Kaldjian1

1RareCyte Inc., Seattle, WA, USA 2University of Washington, Seattle, WA, USA 3Benaroya Research Institute, Seattle, WA, USA

Biomarkers | Checkpoint blockade | Immune monitoring | T cell

P95

Development and application of a 6-channel immunofluorescence assay for investigating PDL1 and IFR1 expression on circulating tumor cells

Lance U'Ren1, Daniel Campton1, Jackie Stilwell1, Eric Kaldjian1

1RareCyte Inc, Seattle, WA, USA

Biomarkers | Checkpoint blockade | Solid tumors

P96

Tumor mutation burden, microsatellite instability and chromosomal instability analysis using low pass whole genome sequencing of single circulating tumor cell

Angel Rodriguez1, Jerry Lee1, Ramsay Sutton1, Rhett Jiles1, Yipeng Wang1, Mark Landers1, Ryan Dittamore1

1Epic Sciences, San Diego, CA, USA

Biomarkers | Bioinformatics | Antigen presenting cells | Genetic polymorphism | Stem cell/cancer-initiating cell

P97

Simultaneous Characterization of Rare Immune cell Subpopulations and PD-L1 expressing CTCs in peripheral blood of cancer patients

Adam Jendrisak1, Angel Rodriguez1, Jiyun Byun1, Ryon Graf1, Yipeng Wang1, Mark Landers1, Ryan Dittamore1

1Epic Sciences, San Diego, CA, USA

Immune tolerance | Immune suppression | Stem cell/cancer-initiating cell | Immune monitoring | Biomarkers | NK/NK T cell

P98

Immunological profiling of baseline and resected biopsies from locally/regionally advanced/recurrent melanoma treated with neoadjuvant combination ipilimumab (3mg/kg or 10mg/kg) and high dose IFN-α2B

Sarah Warren1, Priyanka Vallabhaneni2, Jack El-Sawada2, Andrew White1, Xing Ren1, Alessandra Cesano1, Joseph Beechem1, Ahmad Tarhini2

1NanoString Technologies, Inc., Seattle, WA, USA 2Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Immune contexture | Immune tolerance | Biomarkers | Checkpoint blockade | Clinical study | Immune monitoring

P99

Biomarker analysis from the OpACIN trial (Neo-/adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma)

Lisette (EA) Rozeman1, Lorenzo Franchi1, Thomas Kuilman1, Oscar Krijgsman2, Alexander (ACJ) van Akkooi1, Pia Kvistborg1, Hans van Thienen1, Bauke Stegenga3, Dana Cullen3, Brian Lamon3, John (JBAG) Haanen1, Alessandra Cesano4, Sarah Warren4, Annegien Broeks1, Ton Schumacher1, Christian Blank1

1Netherlands Cancer Institute, Amsterdam, Netherlands 2o.krijgsman@nki.nl, Netherlands, Netherlands 3Bristol-Myers Squibb, Lawrence Township, NJ, USA 4NanoString Technologies, Seattle, WA, USA

Immune contexture | Immune tolerance | Tumor microenvironment | Biomarkers | Checkpoint blockade | Clinical study | Immune monitoring | Tumor evasion

P100

Pretreatment gene expression correlation with clinical response to pembrolizumab or nivolumab in metastatic melanoma

Sarah Warren1, Patrick Danaher1, Tobias Schatton2

1NanoString Technologies, Seattle, WA, USA 2Brigham-Women's Hospital, Boston, MA, USA

Bioinformatics | Immune contexture | Immune tolerance | Biomarkers | Immune suppression

P101

Multiplex Biomarker Detection in FFPE Tumour Samples

Mike Millar1, Louise Welch1, Dawn Lyster1, Mariana Beltran1, Sevi Giakoumelou1

1Aquila BioMedical, Edinburgh, United Kingdom

Tumor microenvironment | Immune monitoring | Biomarkers | Immune contexture | Antigen presenting cells | Myeloid cells | Tumor antigens | B cell | T cell

P102

Mining the periphery for tumor-relevant B and T cells

Katherine L. Williams1, Lukas Pfannenstiel2, Eldar Giladi1, Yvonne Leung1, Xiaobin Tang1, Shuwei Jiang1, Dongkyoon Kim1, Kevin Williamson1, Sean M. Carroll1, Ngan Nguyen1, Gregg Espiritu Santo1, Sini Reponen1, Xiaomu Chen1, Norman M. Greenberg1, Daniel Emerling1, Wayne Volkmuth1, Brian Gastman2, Guy Cavet1

1Atreca, Inc., Redwood City, CA, USA 2Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA

T cell lineages | Immune monitoring | Biomarkers | Antibody | B cell | T cell | Tumor infiltrating lymphocytes (TILs)

P103

Tumor infiltrating lymphocyte (TIL) percentage as a prognostic biomarker for overall and relapse free survival in Hu14.18-IL2 treated resectable recurrent stage 3 or 4 melanoma patients

Richard Yang1, Mark Albertini2, Jacquelyn Hank2, Hans Loibner3, Stephen Gillies4, Paul Sondel2, Erik Ranheim2

1University of Wisconsin - Madison Hospitals and Clinics, Madison, WI, USA 2University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA 3Apeiron Biologics, Vienna, Austria 4Provenance Biopharmaceuticals, Carlisle, MA, USA

Tumor infiltrating lymphocytes (TILs) | Immune monitoring | Clinical trial | Biomarkers | Tumor microenvironment | Targeted therapy | Surgery | Immune contexture | Clinical study | Antibody

P104

A study of PD-L1 diagnostic assay concordance in urothelial carcinoma

Magdalena Zajac1, Marietta Scott1, Marianne Ratcliffe2, Alan Sharpe1, Paul W Scorer1, Craig Barker1, Hytham Al-Masri3, Marlon Rebelatto4, Jill Walker1

1AstraZeneca, Cambridge, United Kingdom 2AstraZeneca, Macclesfield, United Kingdom 3Hematogenix, Tinley Park, IL, USA 4Medimmune, Gaithersburg, MD, USA

Biomarkers | Targeted therapy

P105

Infino: Bayesian inference to distinguish immune cell expression phenotypes, estimate immune infiltration into tumor microenvironment, and investigate exhausted T cell phenotype

Maxim Zaslavsky1, Jacqueline Buros Novik1, Eliza Chang1, Alexander Huang2, Josephine Giles2, Robert Orlowski2, E. John Wherry2, Jeffrey Hammerbacher1

1Icahn School of Medicine at Mount Sinai, New York, NY, USA 2Perelman School of Medicine, Philadelphia, PA, USA

Tumor microenvironment | Biomarkers | Gene expression | Immune contexture | Immunoscore | Tumor infiltrating lymphocytes (TILs)

P106

Bioinformatic analysis of the tumor immune landscape to prioritize combinations with antibody-drug conjugates (ADCs)

Xiaoling Zhang1, Song Wu1, Brandon W. Higgs1, Koustubh Ranade1

1MedImmune, Gaithersburg, MD, USA

Adoptive immunotherapy | Bioinformatics | Chemotherapy | Tumor microenvironment | Checkpoint blockade | Clinical study | Antibody | Gene expression | Solid tumors